Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.42 |
| ▸ | MET | P08581 | 5/20 | 0.41 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.36 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22459240 | 0.96 | TNKS2 (0.41) | TNKS2METAKR1B10AKR1B1PPARG | |
| SCHEMBL22459838 | 0.93 | MET (0.43) | TNKS2METAKR1B10AKR1B1ALOX5 | |
| SCHEMBL22459568 | 0.91 | PPARG (0.39) | TNKS2METAKR1B10AKR1B1PPARG | |
| SCHEMBL22459833 | 0.89 | RARB (0.37) | TNKS2METPPARGPPARA | |
| SCHEMBL22459277 | 0.88 | EGFR (0.37) | TNKS2METAKR1B10AKR1B1ALOX5 | |
| SCHEMBL22459377 | 0.87 | RARB (0.43) | METAKR1B10AKR1B1PPARG | |
| SCHEMBL22459276 | 0.87 | EGFR (0.41) | TNKS2METAKR1B10AKR1B1PPARG | |
| SCHEMBL22459369 | 0.86 | RARB (0.35) | TNKS2METAKR1B10AKR1B1PPARG | |
| SCHEMBL22459412 | 0.85 | LMNA (0.40) | METAKR1B10AKR1B1 | |
| SCHEMBL22459252 | 0.85 | LMNA (0.40) | METAKR1B10AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200299578-A1 | POLYMERIZABLE COMPOUND HAVING METHOXYMETHYL ACRYLIC GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2020-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299578-A1 | POLYMERIZABLE COMPOUND HAVING METHOXYMETHYL ACRYLIC GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | SP1, CCND1, CPNE4 | TNKS2 4341/4885MET 3102/4885AKR1B10 3247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.